{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-007988","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2026-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.156423+00:00","generated_at":"2026-05-16T06:30:51.261407+00:00","sec_items":["1.01","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aprea reports first partial response for APR-1051; raises $5.6M in private placement","bullets":["First unconfirmed partial response (uPR) in PPP2R1A-mutated endometrial cancer at 150 mg: 50% target lesion reduction, CA-125 from 732 to 70 U/mL.","Stable disease at 70 mg (HNSCC, 5% reduction) and 100 mg (colon cancer, 15% reduction; >210 days on therapy).","Private placement ~$5.6M gross: 6.3M shares/pre-funded warrants + 6.3M warrants at $0.765; priced $0.89/unit. Closes Jan 30, 2026.","Dose escalation continues; 220 mg cohort enrolling; company plans to increase HPV-positive enrollment.","Potential dose-response trend observed across 70 mg, 100 mg, and 150 mg cohorts."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-007988","json":"https://secwatch.observer/filing/0001104659-26-007988.json","markdown":"https://secwatch.observer/filing/0001104659-26-007988.md","text":"https://secwatch.observer/filing/0001104659-26-007988.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926007988/0001104659-26-007988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926007988/tm264417d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T06:30:51.261407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"43a797c1527ff364b096d696071162d521ac11f6","claim":"Aprea Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors (the Purchasers) valued at expected aggregate gross proceeds at closing of approximately $5.6 million (effective 2026-01-28).","evidence_excerpt":"On January 28, 2026, Aprea Therapeutics, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) 6,288,857 shares (the “ Private Placement Shares ”) of the Company’s Common Stock, par value $0.001 per share (“ Common Stock ”) or pre-funded Common Stock purchase warrants (the “ Pre-Funded Warrants ”) in lieu thereof, and (ii) common stock purchase warrants to purchase up to 6,288,857 shares of Common Stock (the “ Warrant Shares ”) at an exercise price of $0.765 per share (the “ Common Warrants ” and together with the Pre-Funded Warrants, the “ Warrants ”). The combined effective offering price of each Private Placement Share or Pre-Funded Warrant and accompanying Common Warrant to be issued is $0.89 and represents the “ Minimum Price ” in accordance with Nasdaq","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926007988/0001104659-26-007988-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors (the Purchasers)"},{"label":"Value","value":"expected aggregate gross proceeds at closing of approximately $5.6 million"},{"label":"Effective","value":"2026-01-28"}],"fact_type":"material_agreement"},{"claim_id":"eceb159c691aba29383af63f917c3740d47da4c2","claim":"Aprea Therapeutics, Inc. entered into Registration Rights Agreement with the Company and the Purchasers valued at customary indemnification rights (effective 2026-01-29).","evidence_excerpt":"In connection with the Private Placement, the Company and the Purchasers entered into a Registration Rights Agreement, dated January 29, 2026 (the “ Registration Rights Agreement ”), providing for the registration for resale of Private Placement Shares along with the shares of Common Stock underlying the Pre-Funded Warrants and Common Warrants that are not then registered on an effective registration statement, pursuant to a registration statement (the “ Registration Statement ”) to be filed with the Securities and Exchange Commission (the “ SEC ”) on or prior to the 60 th day after the Closing Date.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926007988/0001104659-26-007988-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the Company and the Purchasers"},{"label":"Value","value":"customary indemnification rights"},{"label":"Effective","value":"2026-01-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}